---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059071"
form_type: "8-K"
ticker: null
cik: "0001971543"
company_name: "Mural Oncology plc"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:23:56.921048+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mural Oncology Q1 2024 net loss $30.9M, cash runway into Q4 2025 reaffirmed

## Summary
- Net loss $30.9M improved from $46.5M Q1 2023; R&D spend $26.9M down 33% YoY.
- Cash, equivalents & marketable securities $231.7M as of March 31, 2024.
- Nemvaleukin alfa registrational trials on track; ARTISTRY-7 interim OS data Q1 2025.
- Less-frequent IV dosing trial for cutaneous melanoma enrolling; preliminary data H1 2025.
- IL-18/IL-12 preclinical data presented at AACR; candidate nominations expected by end 2024.

## SEC filing metadata
- accession: 0000950170-24-059071
- form_type: 8-K
- cik: 0001971543
- company_name: Mural Oncology plc
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971543/000095017024059071/0000950170-24-059071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971543/000095017024059071/mura-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059071
- JSON: https://secwatch.observer/filing/0000950170-24-059071.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059071.txt

## Key facts
- Earnings Releases
  Mural Oncology plc reported first quarter of 2024 results: net income Net loss was $30.9 million. Guidance reaffirmed.
  - Period: first quarter of 2024
  - Net income: Net loss was $30.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Mural Oncology plc (the "Company") issued a press release announcing the Company’s financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000095017024059071/0000950170-24-059071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.